Journal
PHARMACOLOGICAL RESEARCH
Volume 113, Issue -, Pages 449-457Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.phrs.2016.09.001
Keywords
DLL4; DLL4(+) DCs; Notch signaling; Tumor immunity; Alloimmunity and autoimmunity
Categories
Funding
- American Cancer Society
- Department of Defense
- NIH [CA172106, CA178202]
- NIH/NIAMS [R01AR061569]
Ask authors/readers for more resources
Dendritic cells (DCs) are critical regulators of adaptive immune responses. DCs can elicit primary T cell responses at low DC:T cell ratios through their expression of high levels of antigen -presenting molecules and costimulatory molecules. DCs are important for induction of functionally diverse T cell subsets such as CD4(+) T helper (Th)1 and Th17 cells and effector CD8(+) T cells able to reside in epithelial tissues. Recent studies begin illuminating the underlying mechanism by which DCs regulate specialized T cell subsets. DCs are composed of subsets that differ in their phenotype, localization and function. DCs expressing high levels of DLL4 (DLL4(+) DCs), which is a member of Notch ligand family, are newly discovered cells that have greater ability than DLL4(-) DCs to promote the generation of Thl and Th17 CD4(+) T cells. DLL4 derived from DLL4(+) DCs is also important for promoting the differentiation and expansion of effector CDS' T cells. Experimental studies have demonstrated that selective deletion of DLL4 in DCs causes impaired antitumor immunity. In contrast, blocking DLL4 leads to dramatic reduction of inflammatory T cell responses and their -mediated tissue damage. We will discuss emerging functional specialization within the DLL4(+) DC compartment, DLL4(+) DC biology and the impact of pharmacological modulation of DLL4 to control inflammatory disorders. 2016 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available